Is Ceritinib covered by medical insurance? The impact of medical insurance policies on patients

Ceritinib, also known as Ceritinib, is a second-generation targeted drug for ALK-positive non-small cell lung cancer (NSCLC). It has strong targeting and the ability to penetrate the blood-brain barrier. The drug has been officially launched in China and has been included in the national medical insurance directory. This is an important benefit for the majority of lung cancer patients and marks that efficient targeted therapy is gradually becoming accessible and affordable.

After being included in medical insurance, the price of ceritinib has been significantly reduced, and patients’ out-of-pocket expenses have been significantly reduced. Taking common specifications as an example, the actual cost of purchasing medicine after medical insurance varies slightly due to different regional policies, but it is generally several times cheaper than the original price. The implementation of the medical insurance policy has greatly reduced the financial pressure on patients, allowing more patients with ALK-positive lung cancer to take medication regularly for a long time, thus extending their survival and improving their quality of life. For specific medical insurance reimbursement ratios and payment amounts, it is recommended that patients go to the local medical insurance designated hospital pharmacy for consultation and confirmation.

For some patients whose medical insurance cannot cover all costs or who require long-term treatment, overseas generic drugs are also an important option. At present, the price of the Lao version of ceritinib generic drug on the market is about more than 1,000 yuan. Its ingredients are consistent with the original drug and it is highly cost-effective. This generic version is basically equivalent in efficacy to the original drug, but since it is not in the domestic circulation system, patients should obtain it through formal channels and use it under the guidance of professional doctors.

Overall, the inclusion of ceritinib in medical insurance not only improves treatment accessibility for patients, but also reflects my country's policy progress in promoting the affordability of anti-cancer drugs. Whether purchasing original drugs through medical insurance or obtaining generic drugs through formal overseas channels, patients should use drugs scientifically and rationally under the guidance of a doctor to achieve the best therapeutic effect.

Reference materials:https://www.novartis.com/our-products/pipeline/ceritinib